Efmarodocokin alfa

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Efmarodocokin alfa
DrugBank Accession Number
DB16398
Background

Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Fusion proteins
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Efmarodocokin alfa
  • IL 22-FC
  • IL-22Fc
External IDs
  • RG-7880
  • RG7880
  • RO 7021610
  • UTTR1147A

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Efmarodocokin alfa is a human IL-22Fc IgG4 fusion protein that activates the IL-22 pathway being investigated for inflammatory diseases. Studies show activation of STAT3 in primary human hepatocytes and human colon cell lines.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
NYZ11835VX
CAS number
1953227-87-6

References

General References
  1. Rothenberg ME, Wang Y, Lekkerkerker A, Danilenko DM, Maciuca R, Erickson R, Herman A, Stefanich E, Lu TT: Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL-22Fc): A Potential Therapy for Epithelial Injury. Clin Pharmacol Ther. 2019 Jan;105(1):177-189. doi: 10.1002/cpt.1164. Epub 2018 Aug 12. [Article]
  2. Lee DW, Zhong S, Pai R, Rae J, Sukumaran S, Stefanich EG, Lutman J, Doudement E, Wang X, Harder B, Lekkerkerker A, Herman A, Ouyang W, Danilenko DM: Nonclinical safety assessment of a human interleukin-22FC IG fusion protein demonstrates in vitro to in vivo and cross-species translatability. Pharmacol Res Perspect. 2018 Nov 15;6(6):e00434. doi: 10.1002/prp2.434. eCollection 2018 Dec. [Article]
  3. Stefanich EG, Rae J, Sukumaran S, Lutman J, Lekkerkerker A, Ouyang W, Wang X, Lee D, Danilenko DM, Diehl L, Loyet KM, Herman A: Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases. Biochem Pharmacol. 2018 Jun;152:224-235. doi: 10.1016/j.bcp.2018.03.031. Epub 2018 Mar 31. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentUlcerative Colitis1
2CompletedTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID-19 Pneumonia1
2RecruitingTreatmentCrohn's Disease (CD) / Ulcerative Colitis1
1CompletedTreatmentCrohn's Disease (CD) / Ulcerative Colitis1
1CompletedTreatmentNeuropathic Diabetic Ulcer - Foot1
1RecruitingPreventionAcute Graft-Versus-Host Disease (GVHD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 23, 2020 16:16 / Updated on February 21, 2021 18:55